Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Corcept Therapeutics (CORT) Tops Q1 EPS by 12c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Above Consensus
May 4, 2020 4:51 PM EDTCorcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of $0.34, $0.12 better than the analyst estimate of $0.22. Revenue for the quarter came in at $93.2 million versus the consensus estimate of $87.01 million.
Financial Highlights
Revenue of $93.2 million, a 44 percent increase from first quarter 2019GAAP diluted net income of $0.25 per share, compared to $0.15 per share in first quarter 2019Non-GAAP diluted net income of $0.34 per share, compared to $0.20 per share in first quarter 2019Cash and investments of $349.0 million, compared to $315.3 million in fourth quarter 2019Our commercial and medical affairs teams did an excellent... More
